IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-k_562 Homo sapiens myeloid leukemia cells. k562 Myelogenous leukemia K562 cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-d04 Human D04 cells d04 D04 melanoma cells anti tag coip anti tag coimmunoprecipitation anti tag coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-d04 Human D04 cells d04 D04 melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-d04 Human D04 cells d04 D04 melanoma cells anti tag coip anti tag coimmunoprecipitation anti tag coip anti tag western anti tag western blot anti tag western Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-bv173r BV173R- Human imatinib –resistant variant of BV173 expressing T315I mutation Bcr/Abl bv173r BV173R- Human, imatinib –resistant variant of BV173 expressing T315I mutation Bcr/Abl derived from a patient with CML in lymphoblastic crisis anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions mouse-ba_f3 Mouse pro B cells IL-3 dependent mouse-baf3 EBI-6922762 ba_f3 Mouse pro B cells IL-3 dependent BA/F3 baf3 anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Cells were transfected with Human BCR-ABL fusion protein (p185), with or without the T315I mutation, and with or without several other mutations. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-h460 Homo sapiens non-small-cell lung cancer cell line H460 h460 human non-small-cell lung cancer cell line H460 anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-d04 Human D04 cells d04 D04 melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip anti tag western anti tag western blot anti tag western Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-sw620 Human caucasian colon adenocarcinoma SW620 cells sw620 Human caucasian colon adenocarcinoma SW620 cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell (1535-6108) 2011 imex curation Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Only protein-protein interactions human-panc1 Homo sapiens pancreatic carcinoma cell line PANC-1 panc1 Human pancreatic carcinoma cell line PANC-1 Established from a pancreatic carcinoma of ductal origin from a 56-year-old Caucasian male. Cells possess the type B phenotype for G6PD. anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Kinase assays e.g. Fig 2A, NOT annotated as no info regarding the purity of the resultant IP is given - could be loads of kinases IP-ed with the transfected one, and no indication if multiple washing with KCl removed them. Fig S3F not added - RAS capture/Binding assay NOT added as the GST-RBD is a crude bacterial extract, and no info given for source/ species/sequence of RBD. Richard.Marais@icr.ac.uk Accepted 2012-MAR-13 by JYOTI Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation raf1_human RAF proto-oncogene serine/threonine-protein kinase RAF1 RAF Proto-oncogene c-RAF Raf-1 protein protein human Homo sapiens Human MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF DIP protein P04049 original sequence version: 117 DIP protein P04049 original sequence version: 106 DIP protein P04049 original sequence version: 114 DIP protein P04049 original sequence version: 141 DIP protein P04049 original sequence version: 142 DIP protein P04049 original sequence version: 147 DIP protein P04049-1 original sequence version: 136 DIP protein P04049 original sequence version: 136 DIP protein P04049 original sequence version: 153 DIP protein P04049 original sequence version: 150 DIP protein P04049 original sequence version: 164 DIP protein P04049 original sequence version: 172 DIP protein P04049-1 original sequence version: 172 DIP protein P04049 original sequence version: 184 DIP protein P04049 original sequence version: 188 DIP protein P04049 original sequence version: 195 EF821B5349711BC3 rash_human GTPase HRas HRAS HRAS1 Transforming protein p21 p21ras H-Ras-1 c-H-ras Ha-Ras protein protein human Homo sapiens Human MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS DIP protein P01112 original sequence version: 91 DIP protein P01112 original sequence version: 106 DIP protein P01112 original sequence version: 144 DIP protein P01112 original sequence version: 118 DIP protein P01112 original sequence version: 143 DIP protein P01112 original sequence version: 152 DIP protein P01112-1 original sequence version: 159 DIP protein P01112 original sequence version: 170 DIP protein P01112-1 original sequence version: 185 DIP protein P01112 original sequence version: 192 DIP protein P01112-1 original sequence version: 196 DIP protein P01112-1 original sequence version: 202 EE6DC2D933E2856A braf_human Serine/threonine-protein kinase B-raf BRAF BRAF1 RAFB1 v-Raf murine sarcoma viral oncogene homolog B1 p94 Proto-oncogene B-Raf protein protein human Homo sapiens Human MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH DIP protein P15056 original sequence version: 182 DIP protein P15056 original sequence version: 133 DIP protein P15056 original sequence version: 147 DIP protein P15056 original sequence version: 173 DIP protein P15056 original sequence version: 178 DIP protein P15056 original sequence version: 188 DIP protein P15056 original sequence version: 193 DIP protein P15056 original sequence version: 195 DIP protein P15056 original sequence version: 146 DIP protein P15056 original sequence version: 153 0798C2AAB487E813 braf_mouse Serine/threonine-protein kinase B-raf Braf B-raf Proto-oncogene B-Raf protein protein mouse Mus musculus Mouse MAALSGGGGSSSGGGGGGGGGGGGGDGGGGAEQGQALFNGDMEPEAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLVFQTPTDASRNNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPVPQEEASFPETALPSGSSSAPPSDSTGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSSSEDRSRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGGFPVH DIP protein P28028 original sequence version: 109 0643D7F6C44A9A05 raf1_mouse RAF proto-oncogene serine/threonine-protein kinase Raf1 Craf Proto-oncogene c-RAF Raf-1 protein protein mouse Mus musculus Mouse MEHIQGAWKTISNGFGLKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDSSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLQEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTVGDSGVPAPPSFPMRRMRESVSRMPASSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLHVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPGSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQLQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDDNPFSFQSDVYSYGIVLYELMAGELPYAHINNRDQIIFMVGRGYASPDLSRLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF DIP protein Q99N57 original sequence version: 97 DIP protein Q99N57 original sequence version: 132 DIP protein Q99N57 original sequence version: 92 B70104AEF51C44A5 raf1-braf 3 13 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association 2B Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-1 9 11 unspecified role unspecified role bait bait 13 unspecified role unspecified role prey prey physical association physical association 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-2 7 11 unspecified role unspecified role bait bait 13 unspecified role unspecified role prey prey physical association physical association 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-3 10 13 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). braf-raf1-21 2 13 unspecified role unspecified role bait bait P15056:p.Arg188Leu mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain R L Wed May 02 20:15:01 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg188leu' Tue Jun 30 19:40:44 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg188Leu' n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range 11 unspecified role unspecified role prey prey physical association physical association 2D Nilotinib Mutations that prevented BRAF (BRAFR188L) or CRAF (CRAFR89L) binding to RAS blocked BRAF binding to CRAF. raf1-braf-4 2 13 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait P04049:p.Arg89Leu mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain R L Wed May 02 16:16:48 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg89leu' Tue Jun 30 17:19:01 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg89Leu' n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association 2E Nilotinib Mutations that prevented BRAF (BRAFR188L) or CRAF (CRAFR89L) binding to RAS blocked BRAF binding to CRAF. braf-braf1-22 4 13 unspecified role unspecified role bait bait n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range P15056:p.Thr529Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain T N Wed May 02 15:36:08 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'thr529asn' Tue Jun 30 18:39:07 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Thr529Asn' 13 unspecified role unspecified role prey prey n_terminus ha tag ha tag YPYDVPDYA epitope tag YPYDVPDYA epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association 2G, 2I. Nilotinib BRAF and CRAF homodimers were formed in D04 cells (Figures 2F and 2G). Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. raf1-raf-5 4 11 unspecified role unspecified role prey prey n_terminus ha tag ha tag YPYDVPDYA epitope tag YPYDVPDYA epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range 11 unspecified role unspecified role bait bait n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association 2F Nilotinib BRAF and CRAF homodimers were formed in D04 cells (Figures 2F and 2G). raf1-braf-6 8 11 unspecified role unspecified role bait bait 13 unspecified role unspecified role prey prey P15056:p.Thr529Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain T N Wed May 02 19:23:33 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'thr529asn' Tue Jun 30 20:05:13 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Thr529Asn' n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association 2H Nilotinib and Imatinab. Mutations BRAF T529N and CRAF T421N were severely impaired in their ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. raf1-raf1-1 4 11 unspecified role unspecified role bait bait n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range P04049:p.Thr421Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain T N Wed May 02 20:15:22 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'thr421asn' Tue Jun 30 20:02:29 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Thr421Asn' 11 unspecified role unspecified role prey prey n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association 2J Nilotinib Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. Bait tags are different from otherwise similar Fig 2F - so this interaction entered as a new one. braf-raf1-22 2 11 unspecified role unspecified role prey prey 13 unspecified role unspecified role bait bait P15056:p.Arg188Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain R N Wed May 02 17:47:19 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg188asn' Tue Jun 30 18:50:34 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg188Asn' n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range physical association physical association S2B Dastinib Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. braf-raf1-24 6 15 unspecified role unspecified role prey prey 14 unspecified role unspecified role bait bait physical association physical association 3C, 4G, 5F, S3C, S3D. Imatinib, nilotinib, and dasatinib did not affect BRAF binding to CRAF in BCR-ABL cells, but they enhanced BRAF binding to CRAF in BCR-ABL T315I Ba/F3 cells. Imatinib, nilotinib, and dasatinib, in BCR-ABL T315I Ba/F3 cells. BRAF selective inhibitors SB590885 and L779450, enhanced BRAF binding to CRAF in BCR-ABL Ba/F3 cells. pan-RAF inhibitors sorafenib and RAF265 induced BRAF binding to CRAF in BCR-ABL T315I Ba/F3 cells. BRAF inhibitor PLX4720 and the MEK inhibitor PD184352 , induced only weak BRAF binding to CRAF, in BCR-ABL T315I Ba/F3 cells. Cells expressing BCR-ABL G250E/T315I, BCR-ABL E255K/T315I, or BCR-ABL E255V/T315 induced BRAF binding to CRAF. raf1-braf-7 5 13 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association 3E Imatinib, nilotinib, and dasatinib imatinib, nilotinib, and dasatinib did not induce BRAF binding to CRAF in BV173 cells, but they did induce BRAF binding to CRAF in BV173R cells, which express BCR-ABL T315I. raf1-braf-9 1 12 unspecified role unspecified role ancillary ancillary P01112:p.Gly12Val mutation mutation certain certain sequence position certain certain certain sequence position certain G V Wed May 02 20:14:32 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'gly12val' Tue Jun 30 16:00:33 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Gly12Val' 11 unspecified role unspecified role bait bait 13 unspecified role unspecified role prey prey physical association physical association 4C Imatinib, nilotinib, and dasatinib imatinib, nilotinib, and dasatinib did not induce BRAF binding to CRAF in K562 cells (which express BCR-ABL), but when these cells expressed HRAS - G12V, all three drugs induced BRAF binding to CRAF. raf1-braf-10 1 11 unspecified role unspecified role bait bait 13 unspecified role unspecified role prey prey physical association physical association S3E nilotinib BRAF binding to CRAF was observed in K562R cells (a clone of K562 cells that is resistant to Imatinib due to overexpression of the SRC family kinase LYN).